Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) revealed that it has been selected as a headline partner for a major psychedelics conference to be held virtually in June.
The Vancouver-based company said that it will act as a main partner for the PSYCH: The Psychedelics Symposium, which is scheduled to run between June 22 to 23, 2020.
Champignon specializes in formulizing a suite of medicinal mushroom health products and ketamine to treat a broad range of disorders.
This year’s PSYCH conference comes at a time when the potential for using psychedelics to treat more mainstream health concerns is widening. Champignon is one of the first pure-play psychedelic companies to IPO on a major exchange and is quickly assembling a portfolio of clinical, drug delivery and research assets.
The impact of the coronavirus pandemic has put greater emphasis on the importance of mental health, according to Stephen Murphy, managing director at Prohibition Partners, which is producing the virtual event.
“Consumers are looking for options to improve their mental health and, as the body of evidence mounts for psychedelics, the healthcare industry is responding with solutions,” Murphy said in a statement. “We’re delighted to partner with Champignon Brands on PSYCH and support their vision of improving mental health via psychedelics.”
During the event, participants can livestream keynotes and panels from over 150 executives and policymakers presenting new findings and expert analysis on the state of the nascent industry.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas